Predicting Future Price Moves In Humacyte Inc (HUMA)

Humacyte Inc (NASDAQ:HUMA) does about 2.02M shares in volume on a normal day but saw 1461454 shares change hands in Monday trading. The company now has a market cap of 857.38M USD. Its current market price is $7.20, marking a decrease of -0.96% compared to the previous close of $7.27. The 52 week high reached by this stock is $9.97 whilst the lowest price level in 52 weeks is $1.96.

Humacyte Inc (HUMA) has a 20-day trading average at $7.11 and the current price is -27.78% off the 52-week high compared with 267.35% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.04 and its 200-day simple moving average is $3.54. If we look at the stock’s price movements over the week, volatility stands at 12.77%, which increases to 13.34% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 57.10 to suggest the stock is neutral.

The consensus objective for the share price is $8.40, suggesting that the stock has a potential upside of 14.29% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 11, 2023 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $6. Piper Sandler upgraded the stock to “Neutral” from Underweight on August 14, 2023 at a price target of $2.75-$3.50. Cantor Fitzgerald initiated its price target at $6.

Humacyte Inc (HUMA) stock is down -2.31% over the week and 59.29% over the past month. Its price is 153.52% year-to-date and 69.41% over the past year.

The company’s next earnings report forecasts estimating quarterly EPS at -0.24 and -0.99 for whole year. Expected sales for next quarter are $480k, which analysts say will come at $2.95M for the current fiscal year and next year at $30.85M.

To reach the target analysts have set, the stock logically needs to grow 14.29 percent from here.

The company has a return on investment of -251.66% and return on equity of -195.68%. The beta has a value of 1.61. Price to book ratio is 32.79.